Astellas Bid To Buy OSI Of U.S. For $3.5 Billion Draws Promise To Review
This article was originally published in PharmAsia News
Executive Summary
The bid by Astellas Pharmaceuticals to buy U.S.-based OSI Pharmaceuticals for $3.5 billion has drawn a response from OSI that it would review the offer